Trillium Therapeutics Competitors

Cronos Group (TSE:CRON) and Trillium Therapeutics (TSE:TRIL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for Cronos Group and Trillium Therapeutics, as provided by MarketBeat.com.

Cronos Group presently has a consensus price target of C$9.68, suggesting a potential downside of 7.19%. Trillium Therapeutics has a consensus price target of C$25.00, suggesting a potential upside of 100.32%. Given Trillium Therapeutics' higher possible upside, analysts plainly believe Trillium Therapeutics is more favorable than Cronos Group.

Earnings and Valuation

This table compares Cronos Group and Trillium Therapeutics' revenue, earnings per share and valuation.

Trillium Therapeutics has lower revenue, but higher earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cronos Group and Trillium Therapeutics' net margins, return on equity and return on assets.

Summary

Trillium Therapeutics beats Cronos Group on 4 of the 7 factors compared between the two stocks.

Concordia International (TSE:CXR) and Trillium Therapeutics (TSE:TRIL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Concordia International and Trillium Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Concordia International has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Concordia International and Trillium Therapeutics, as provided by MarketBeat.

Trillium Therapeutics has a consensus price target of C$25.00, suggesting a potential upside of 100.32%.

Profitability

This table compares Concordia International and Trillium Therapeutics' net margins, return on equity and return on assets.

Summary

Concordia International beats Trillium Therapeutics on 4 of the 4 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and Trillium Therapeutics (TSE:TRIL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Aptose Biosciences and Trillium Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Aptose Biosciences has higher earnings, but lower revenue than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Aptose Biosciences and Trillium Therapeutics, as provided by MarketBeat.

Aptose Biosciences presently has a consensus price target of C$12.00, suggesting a potential upside of 87.21%. Trillium Therapeutics has a consensus price target of C$25.00, suggesting a potential upside of 100.32%. Given Trillium Therapeutics' higher probable upside, analysts plainly believe Trillium Therapeutics is more favorable than Aptose Biosciences.

Profitability

This table compares Aptose Biosciences and Trillium Therapeutics' net margins, return on equity and return on assets.

Summary

Aptose Biosciences beats Trillium Therapeutics on 3 of the 5 factors compared between the two stocks.

Trillium Therapeutics (TSE:TRIL) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares Trillium Therapeutics and Burcon NutraScience's top-line revenue, earnings per share and valuation.

Burcon NutraScience has lower revenue, but higher earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Trillium Therapeutics and Burcon NutraScience, as reported by MarketBeat.com.

Trillium Therapeutics currently has a consensus target price of C$25.00, suggesting a potential upside of 100.32%. Burcon NutraScience has a consensus target price of C$5.00, suggesting a potential downside of 2.91%. Given Trillium Therapeutics' higher probable upside, research analysts clearly believe Trillium Therapeutics is more favorable than Burcon NutraScience.

Profitability

This table compares Trillium Therapeutics and Burcon NutraScience's net margins, return on equity and return on assets.

Summary

Burcon NutraScience beats Trillium Therapeutics on 5 of the 7 factors compared between the two stocks.

Trillium Therapeutics (TSE:TRIL) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Earnings & Valuation

This table compares Trillium Therapeutics and BELLUS Health's gross revenue, earnings per share and valuation.

BELLUS Health has lower revenue, but higher earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Trillium Therapeutics and BELLUS Health, as reported by MarketBeat.

Trillium Therapeutics currently has a consensus target price of C$25.00, indicating a potential upside of 100.32%. Given Trillium Therapeutics' higher probable upside, equities analysts plainly believe Trillium Therapeutics is more favorable than BELLUS Health.

Profitability

This table compares Trillium Therapeutics and BELLUS Health's net margins, return on equity and return on assets.

Summary

BELLUS Health beats Trillium Therapeutics on 5 of the 7 factors compared between the two stocks.

Trillium Therapeutics (TSE:TRIL) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Earnings & Valuation

This table compares Trillium Therapeutics and Theratechnologies' gross revenue, earnings per share and valuation.

Theratechnologies has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Trillium Therapeutics and Theratechnologies, as reported by MarketBeat.

Trillium Therapeutics currently has a consensus target price of C$25.00, indicating a potential upside of 100.32%. Theratechnologies has a consensus target price of C$3.75, indicating a potential downside of 17.04%. Given Trillium Therapeutics' higher probable upside, equities analysts plainly believe Trillium Therapeutics is more favorable than Theratechnologies.

Profitability

This table compares Trillium Therapeutics and Theratechnologies' net margins, return on equity and return on assets.

Summary

Theratechnologies beats Trillium Therapeutics on 4 of the 6 factors compared between the two stocks.